News

CAMBRIDGE, UK (2018-05-17) – ProteinLogic attended 19th Bio€quity Europe event, held in Ghent, Belgium. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected presenting companies. ProteinLogic was invited to present to a panel of investors and life-science professionals, garnering significant interest. Further panel discussions of significant interest included topics on access to the Chinese market and investment, as well as the future of EU Biotech. Further information: info@proteinlogic.com ProteinLogic ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products…

CAMBRIDGE, UK (2018-04-26) – ProteinLogic attended BioTrinity 2018, Europe’s leading biopartnering and investment conference. During the event, ProteinLogic delegates took advantage of the partnering environment to provide exposure of our technology, and our validated TB diagnostic to investors and life-sciences key players. The event included panel discussions of significant interest, especially regarding market access globally, the new life-science investment landscape, and alternative sources of funding. Further information: info@proteinlogic.com ProteinLogic ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel…

CAMBRIDGE UK (2018- 03- 05) –  ProteinLogic, the biomarker discovery and exploitation company has appointed Darleen Welford as VP of Regulatory Affairs and Quality Assurance (RA/QA) to bring valuable global regulatory expertise, and to further the company’s RA strategy. Darleen has over 19 years’ experience in the field of In Vitro Diagnostic Medical Devices and brings with her a variety of regulatory and quality skills across the whole product life cycle, including experience of global product registrations, risk management, quality management systems and clinical study management. Before joining ProteinLogic, Darleen worked in similar roles in the IVD sector, where she…

CAMBRIDGE, UK (2018-02-19) – ProteinLogic, the biomarker discovery company, has appointed Dr Nicolas Huber as its Chief Executive Officer. Dr Huber holds a Masters degree in electronic engineering and a PhD in Space Science from the University of Sussex. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past 8 years has been focused on medical device research and commercialization. Most recently he has developed a new portfolio of devices for the treatment of cancer, and built a product development team and new business line within an established multinational. Dr Huber during this time…

ProteinLogic attended the 48th Union World Conference on Lung Health held in Guadalajara, Mexico, held on 11th-14th October 2017.  The conference theme was  ‘Accelerating Toward Elimination’. There was a focus on how to accelerate toward elimination of Tuberculosis. Numerous prominent scientists and global thought leaders emphasised the need for pro-active steps to find people with Active TB and the importance of blood based rule-out triage test for Active TB. Delegates from more than 100 countries attended the four-day scientific programme of plenaries, symposia and abstracts presented by experts from around the world. The conference saw debate and discussion from public…

CAMBRIDGE, UK (2017-08-30) – ProteinLogic, a biomarker discovery company, funded by a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB), has achieved a significant milestone. In 2015, 10.4 million people fell ill with TB and 1.8 million died from the disease. Over 95% of TB deaths occur in low and middle-income countries. Whilst TB incidence has fallen by an average of 1.5% per year since 2000, there is an urgent need to accelerate this to a 4–5% annual decline. The World Health Organisation has set a…

CAMBRIDGE, UK (2016-05-03) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Alex Betz as Chief Scientific Officer to manage the scientific, research, technological and developmental operations. As a long standing non-executive director of the Company, Alex has helped set the company research and scientific priorities so that they line up with the overall mission and goals of the Company Dr Betz completed a PhD on the hypermutation of immunoglobulin genes at the MRC Laboratory of Molecular Biology, Cambridge UK. After 3.5 years working as a post-doc at the Howard Hughes Medical Institute, Johns Hopkins University, Baltimore USA,…